Trial using Nine Weeks of herceptin-based chemo published

Public Archive
1

Trial using Nine Weeks of herceptin-based chemo published

2

Trial using Nine Weeks of herceptin-based chemo published Hi everyone,

Today the New England Journal of Medicine published the article ‘Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer’. These are the results from the Finnish trial that used just nine-weeks of herceptin + taxotere followed by nine weeks of FEC60 and had a reduction in recurrence of 58% without any heart problems whatsoever. This was a smaller trial, so the range of actual benefit from the treatment may be anywhere from a 21% to 83% reduction in recurrence. It is not known yet whether this is as good as a year of herceptin including herceptin-based chemo. The result could be very important, though, for patients who are at greater risk of heart trouble, as well as those who cannot get the drug otherwise.

3

Thanks Interesting results

Jane